fbpx
Skip to main content

Mets ace Kodai Senga (shoulder) won’t throw for 3 weeks

Feb 19, 2024; Port St. Lucie, FL, USA; New York Mets starting pitcher Kodai Senga (34) warms-up during workouts at spring training. Mandatory Credit: Jim Rassol-USA TODAY Sports
Credit: Jim Rassol-USA TODAY Sports

New York Mets No. 1 starter Kodai Senga had a platelet-rich plasma injection in his ailing right shoulder and won’t throw for at least three weeks, all but sealing that he won’t take the mound as the team’s Opening Day starter.

Manager Carlos Mendoza told reporters at spring training on Sunday in Port St. Lucie, Fla., that Senga had returned to camp after traveling to New York for diagnosis and treatment.

The 31-year-old Senga was diagnosed with a moderate posterior capsule strain in his pitching shoulder after an MRI test last Wednesday. Mendoza said the hope is the shot will accelerate the healing.

“Let the shot do the work and the once we start ramping up his throwing program we’ll have a better idea how he’s bouncing back and all that,” Mendoza said. “We got to let it heal.”

Once doctors give him the green light to throw, he still will need the time he would have had in spring training to prepare for the regular season, meaning he likely will be on the injured list when the Mets open the season March 28 at home against the Milwaukee Brewers.

The Mets had the MRI performed after Senga reported shoulder fatigue following his bullpen sessions in spring training.

Senga was an All-Star and finished second in National League Rookie of the Year voting last year after going 12-7 with a 2.98 ERA in 29 starts. He threw 166 1/3 innings.

Senga pitched in 275 games, racking up 1,340 2/3 innings across 11 seasons in Japan before signing with the Mets.

Senga is entering the second season of a five-year, $75 million contract he signed with the Mets in December 2022.

He is expected to anchor a rotation that includes Jose Quintana, Luis Severino, Sean Manaea and Adrian Houser.

–Field Level Media

Mentioned in this article:

More About: